Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$21.7K Hold
414
0.01% 873
2026
Q1
$22.8K Hold
414
0.01% 876
2025
Q4
$20.3K Hold
414
0.01% 903
2025
Q3
$17.9K Buy
414
+413
+41,300% +$16.1K 0.01% 931
2025
Q2
$38 Buy
+1
New +$38 ﹤0.01% 2172

Other funds holding GSK

Essential Partners's GSK Position: Q2 2026 in Review

Essential Partners held its GSK (GSK) position steady in Q2 2026 at 414 shares worth $21.7K. The position accounts for 0.01% of the portfolio, ranked #873.

Essential Partners first reported a position in GSK in Q2 2025 and has held it in 5 quarters since. The position peaked at $22.8K in Q1 2026. 1,038 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

  • Essential Partners held 414 shares of GSK worth $21.7K as of Q2 2026.
  • Essential Partners left its GSK share count unchanged in Q2 2026.
  • GSK made up 0.01% of Essential Partners's portfolio in Q2 2026, its #873 holding.
  • Essential Partners first reported a position in GSK in Q2 2025 and has held it in 5 quarters since.
  • Essential Partners's GSK position peaked at $22.8K in Q1 2026.
  • 1,038 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.